Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 30, pp. 3489-3500
Closed Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Marwan Fakih, Lisa Salvatore, Taito Esaki, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 23, pp. 2125-2139
Closed Access | Times Cited: 161
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Naresh Bumma, Joshua Richter, Sundar Jagannath, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 22, pp. 2702-2712
Open Access | Times Cited: 21
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Takafumi Koyama, Toshio Shimizu, Yuki Kojima, et al.
Cancer Discovery (2023) Vol. 13, Iss. 8, pp. 1814-1825
Open Access | Times Cited: 26
Nucleic acid-based drugs for patients with solid tumours
Sebastian G. Huayamares, David Loughrey, Hyejin Kim, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 6, pp. 407-427
Closed Access | Times Cited: 13
Exploiting temporal aspects of cancer immunotherapy
Rachael M. Zemek, Valsamo Anagnostou, Inês Pires da Silva, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 7, pp. 480-497
Closed Access | Times Cited: 13
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Daniel C. Kirouac, Cole Zmurchok, Denise Morris
npj Systems Biology and Applications (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
C. Benedikt Westphalen, Diogo Martins-Branco, Juliana Rodrigues Beal, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 936-953
Open Access | Times Cited: 10
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
Yang Peng, Daniel Li, Ruitao Lin, et al.
Statistics in Medicine (2024) Vol. 43, Iss. 15, pp. 2972-2986
Open Access | Times Cited: 8
Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development
Wei Gao, Jiang Liu, Blerta Shtylla, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 5, pp. 691-709
Open Access | Times Cited: 20
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
Alfonso López de Sá, Cristina Díaz‐Tejeiro, Elisa Poyatos‐Racionero, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 16
2023 White Paper on Recent Issues in Bioanalysis: EU IVDR 2017/746 Implementation/Impact, IVD/CDx/CLIA Approved Assays, High Dimensional Cytometry, Multiplexing Technologies, LBA Tissue Analysis, Vaccine Study Endpoints, Cell-Based Assays for Biomarkers, Cell Therapy and Vaccines ( PART 2 – Recommendations on Development & Validation of Biomarkers, IVD, CDx, Cell-Based, Flow Cytometry, Ligand-Binding and Enzyme Assays; Advanced Critical Reagents Strategies)
Olga Kholmanskikh, Yow‐Ming Wang, Sarah Hersey, et al.
Bioanalysis (2024) Vol. 16, Iss. 8, pp. 179-220
Open Access | Times Cited: 7
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
Divya Samineni, Karthik Venkatakrishnan, Ahmed A. Othman, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 3, pp. 531-545
Open Access | Times Cited: 6
Dose Optimization in Oncology Drug Development: The Emerging Role of Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics
Apostolos Papachristos, Jai N. Patel, Maria Vasileiou, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3233-3233
Open Access | Times Cited: 16
Precision Oncology: 2023 in Review
Yonina R. Murciano‐Goroff, Sarah P. Suehnholz, Alexander Drilon, et al.
Cancer Discovery (2023) Vol. 13, Iss. 12, pp. 2525-2531
Open Access | Times Cited: 16
Automatic deep learning method for third lumbar selection and body composition evaluation on CT scans of cancer patients
Lidia Delrieu, D Blanc, Amine Bouhamama, et al.
Frontiers in Nuclear Medicine (2024) Vol. 3
Open Access | Times Cited: 5
Sex differences in the pharmacokinetics of anticancer drugs: a systematic review
J Delahousse, Dorothea Wagner, Sven Borchmann, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 104002-104002
Open Access | Times Cited: 5
Dose optimization during drug development: whether and when to optimize
Edward L. Korn, Jeffrey A. Moscow, Boris Freidlin
JNCI Journal of the National Cancer Institute (2022) Vol. 115, Iss. 5, pp. 492-497
Open Access | Times Cited: 20
Statistical and practical considerations in planning and conduct of dose-optimization trials
Ying Yuan, Heng Zhou, Suyu Liu
Clinical Trials (2024) Vol. 21, Iss. 3, pp. 273-286
Open Access | Times Cited: 4
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
Anyue Yin, G. Veerman, J. G. Coen van Hasselt, et al.
CPT Pharmacometrics & Systems Pharmacology (2024) Vol. 13, Iss. 4, pp. 612-623
Open Access | Times Cited: 4
N-of-1 medicine
Peter Wang, Qiao Ying Leong, Ni Yin Lau, et al.
Singapore Medical Journal (2024) Vol. 65, Iss. 3, pp. 167-175
Open Access | Times Cited: 4
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus
Peter F. Thall, Elizabeth Garrett‐Mayer, Nolan A. Wages, et al.
Clinical Trials (2024) Vol. 21, Iss. 3, pp. 267-272
Open Access | Times Cited: 4
Dose Optimization of Targeted Therapies for Oncologic Indications
Marjorie E. Zettler
Cancers (2024) Vol. 16, Iss. 12, pp. 2180-2180
Open Access | Times Cited: 4
Aptamer-Modified Nb2C Multifunctional Nanomedicine for Targeted Photothermal/Chemotherapy Combined Therapy of Tumor
Meiqing Liu, Lu Zhao, Yuying Chen, et al.
Molecular Pharmaceutics (2024)
Closed Access | Times Cited: 4
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
Catharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. e340-e351
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top